Telix Pharmaceuticals (TLX) Stock: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$11.29
-0.61 (-5.13%)
▼
5d:
-3.83%
30d:
-5.68%
90d:
+19.47%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Jul 02, 2026
0d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TLX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TLX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.14
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $11.29, which is considered extended relative to its 30-day fair value range of $10.89 to $12.12. From a valuation perspective, the stock is trading at a premium (Forward PE: 55.6) compared to its historical average (30.7). At these levels, the market is pricing in 21.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. Immediate support is located at $10.80, while resistance sits at $12.48. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: TLX scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.45 (+90.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TLX is in a strong downtrend. Immediate support is located at $10.80, while resistance sits at $12.48. Short-term momentum is weak, with the stock down 5.1% recently.
Market Sentiment: TLX scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.45 (+90.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.89 -
$12.12
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.9%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.1%)
- BULLISH: Trading 90.0% below Wall St target ($21.45)
- NEUTRAL: Trading at premium valuation - market expects 21.9% growth which is achievable
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.89 -
$12.12
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$10.80
Resistance Level
$12.48
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
55.62
Wall Street Target
$21.45
(+90.0%)
Revenue Growth (YoY)
22.3%
Profit Margin
3.8%
Valuation Premium vs History
+21.9% premium
PE vs Historical
55.6 vs 30.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.9%
(market-implied from PE analysis)
1-Year Target
$13.76
(+22%)
2-Year Target
$16.78
(+49%)
3-Year Target
$20.45
(+81%)
3-Yr Target (if PE normalizes)
(PE: 56→31)
PE COMPRESSION
$11.29
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 55.6, Growth: 31.6%)
$25.76
(+128%)
Base:
(SPY PE: 20.2, Growth: 31.6%)
$9.34
(-17%)
Bear:
(PE: 17.1, Growth: 31.6%)
$7.94
(-30%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (156x PE), but valuation improves significantly next year (56x PE) as earnings recover.
Forward PE: 156.25 | Forward EPS (Implied): $0.07
Bull Case
$13.63
(+21%)
Analyst growth 15.0%, PE expands to 164.1
Base Case
$11.29
(0%)
Market implied 0.0%, PE stable at 156.3
Bear Case
$8.64
(-24%)
Severe decline -15.0%, PE contracts to 140.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 6:40 AM ET
Data refreshes hourly during market hours. Next update: 7:40 AM
Data refreshes hourly during market hours. Next update: 7:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
